ライフサイエンスコーパス: splenectomy

1 to undergo an MRI scan, or had a history of splenectomy.

2 ed with 1.7% in patients who did not undergo splenectomy.

3 ate (>/=90 days; HR 1.5 [CI, 0.9-2.6]) after splenectomy.

4 iesis-dependent iron consumption by means of splenectomy.

5 ents with refractory disease usually require splenectomy.

6 76 patients with ITP, 1762 of whom underwent splenectomy.

7 of response to rituximab and the response to splenectomy.

8 -8.5]) and late (HR 2.7 [CI, 1.9-3.8]) after splenectomy.

9 nosis of accessory spleens in patients after splenectomy.

10 cancers, granulomatous disease, or previous splenectomy.

11 , 1.39-2.01) among the 19 states in rates of splenectomy.

12 sthesia, instrumentation for monitoring, and splenectomy.

13 gths, and more commonly involved concomitant splenectomy.

14 nts were incidences of treatment failure and splenectomy.

15 ents develop massive splenomegaly or undergo splenectomy.

16 extramedullary hematopoiesis and preventing splenectomy.

17 of IgM(+) CD27(+) memory B cells found after splenectomy.

18 ell ablative therapies such as anti-CD20 and splenectomy.

19 , but fails to protect septic mice following splenectomy.

20 ear lower following rituximab than following splenectomy.

21 y is before splenectomy, or after failure of splenectomy.

22 ti-D, intravenous immunoglobulin (IVIG), and splenectomy.

23 patient), AMR was treated with laparoscopic splenectomy.

24 cannot tolerate, or are unwilling to undergo splenectomy.

25 to standard therapy (ST) who resolved after splenectomy.

26 ease from bone marrow, a process enhanced by splenectomy.

27 n the outcomes of ITP patients refractory to splenectomy.

28 9.6% (88 of 921 patients) with laparoscopic splenectomy.

29 ) had gastric variceal bleeding and required splenectomy.

30 t an ITP second-line treatment: Rituximab or splenectomy.

31 reported consistently predicted response to splenectomy.

32 Overall, 9 (20%) donors underwent splenectomy.

33 Nissen fundoplication, cholecystectomy, and splenectomy.

34 if MCC vaccination occurred <10 years after splenectomy.

35 ous congenital anemias who underwent partial splenectomy.

36 n causing severe infection in patients after splenectomy.

37 of severe sepsis and septic shock following splenectomy.

38 This defect resolved after splenectomy.

39 o patients who received observation required splenectomy.

40 patient underwent total pancreatectomy with splenectomy.

41 nd 1 patient had a distal pancreatectomy and splenectomy.

42 nd stress the relevance of vaccination after splenectomy.

43 mplications and mortality following elective splenectomy.

44 rocedural management, angioembolization, and splenectomy.

45 asive bacterial infection, notably following splenectomy.

46 onset, intravascular hemolysis, and previous splenectomy.

47 ent urgent right hepatic artery ligation and splenectomy.

48 plenectomy and depends on the indication for splenectomy.

49 e common for all other procedures, including splenectomy (0.7% MIS), common bile duct exploration (24

50 twenty-three children underwent laparoscopic splenectomy (211 total; 12 partial) by the lateral appro

51 management strategy (195 patients undergoing splenectomy [23.6%], 70 undergoing angioembolism [23.9%]

52 index hospitalization, 825 (21.8%) underwent splenectomy, 293 (7.7%) underwent angioembolization, and

53 05) with a trend toward worsened response to splenectomy (3 of 18, 17%; vs 36 of 86, 42%; P = .06).

54 Of 33,131 patients, 26.2% underwent splenectomy, 6.1% died, and median hospital costs were $

55 leen in ischemic injury, we found that prior splenectomy (-7d) or chemical sympathectomy of the splee

56 Finally, splenectomy abrogated the enhancing effects of poly (I:C

57 led hypertension, previous aneurysm surgery, splenectomy, acute aortic dissection, aneurysm type, old

58 1), trocar site hernia (1), subsequent total splenectomy after an initial partial (1), and recurrent

59 However, the chance of readmission for splenectomy after initial nonoperative management was 1.

60 predicted sustained responses whereas prior splenectomy, age, sex, and duration of ITP did not.

61 the frequency of surgical complications with splenectomy all remain uncertain.

62 afts with this severe AMR phenotype by using splenectomy alone (n=14), eculizumab alone (n=5), or spl

63 very high load of PCs may not be rescued by splenectomy alone and may need additional treatments.

64 These data suggest that splenectomy alone may not be the sole reason for loss of

65 udies show that corticosteroid treatment and splenectomy, alone or together, increase platelet counts

66 There was more chronic glomerulopathy in the splenectomy-alone and eculizumab-alone groups at 1 year,

67 At a median follow-up of 533 days, 4 of 14 splenectomy-alone patients experienced graft loss (media

68 Splenectomy also was performed less frequently in patien

69 s 11.1% among the ITP patients who underwent splenectomy and 10.1% among the patients who did not.

70 Gender, age, ABO blood-type, cold ischemia, splenectomy and allograft type were significant DSA pred

71 However, splenectomy and anti-CD20 is associated with an increase

72 is high in patients who previously underwent splenectomy and depends on the indication for splenectom

73 defined as a normal platelet count following splenectomy and for the duration of follow-up with no ad

74 ecommended only in patients at high risk for splenectomy and in those not willing to undergo surgery.

75 actors that improved platelet responses were splenectomy and increasing patient age.

76 ), and 4 months after transplantation (after splenectomy and on maintenance immunosuppression).

77 The interval between splenectomy and OPSI was 6 years (range, 1 month-50 year

78 discuss criteria for treatment, the roles of splenectomy and other treatment options along with their

79 variate analysis suggested an interaction of splenectomy and perioperative transfusion in their effec

80 Associations between incidental splenectomy and risk of mortality and severe infections

81 As second-line therapy, splenectomy and Rituximab are both recommended.

82 the treatment of the disease has changed as splenectomy and rituximab have been shown to have unexpe

83 est triage model for decision making between splenectomy and SAE (AUC, 0.84).

84 Unlike adrenalectomy, splenectomy and splenic neurectomy prevent the anti-infl

85 cells promote MPE formation, as indicated by splenectomy and splenocyte restoration experiments.

86 und in patients (n=3) who did not respond to splenectomy and subsequently underwent bortezomib treatm

87 sly defined as lack of a minimum response to splenectomy and the requirement for long-term treatment

88 of studies comparing second-line options to splenectomy and to each other.

89 were retreated with cladribine, 3 underwent splenectomy, and 1 received pentostatin.

90 All patients in group 1 underwent emergent splenectomy, and all patients in group 2 were initially

91 ry spleen) and laparoscopic in 2 (completion splenectomy, and cyst excision).

92 ncluding gastrojejunostomy, cholecystectomy, splenectomy, and distal pancreatectomy have been perform

93 nt correlation between methemoglobin levels, splenectomy, and factors that modify the degree of globi

94 rpura for more than 3 months, had a previous splenectomy, and had a platelet count less than 50 x 10(

95 use of rituximab, increased plasma exchange, splenectomy, and immunosuppressive options, including cy

96 cium, pre-transfusion hemoglobin, history of splenectomy, and liver iron concentration.

97 onor-specific antibody, absence of recipient splenectomy, and liver-inclusive graft type.

98 he increased thrombotic risk associated with splenectomy, and patients with hemoglobinopathies is a p

99 orbidity (including leaks, wound dehiscence, splenectomy, and postoperative hemorrhage) occurred in 2

100 s, type of immunosuppression, recipient age, splenectomy, and treatment of rejection were significant

101 imus and sirolimus maintenance therapy, with splenectomy, anti-CD20 and daily alpha-Gal polymer.

102 ren with hereditary spherocytosis, a partial splenectomy appears to control hemolysis while retaining

103 rituximab leads to response rates similar to splenectomy ( approximately 70%), but rituximab-induced

104 Patients who undergo splenectomy are at greatly increased risk for overwhelmi

105 raft recipients, and particularly those with splenectomy are at high risk of developing GVHD after tr

106 We conclude that ITP patients post splenectomy are at increased risk for AbVTE, VTE, and se

107 Because patients who have undergone splenectomy are considered at increased risk of bacteria

108 , vincristine, or cyclosporine A; or salvage splenectomy are considered.

109 erm risks, the indications for and timing of splenectomy are debated in the medical community.

110 Advanced age and splenectomy are risk factors for PAH in this patient pop

111 Laparoscopic splenectomy as an alternative to open splenectomy for sp

112 Because subjects with autoimmunity had splenectomy at a significantly older age than participan

113 included transfusion-dependent anemia until splenectomy at age 3 and increasing muscle weakness, wit

114 l involving pretransplant plasmapheresis and splenectomy at the time of transplant (n=23).

115 eadmitted patients (4.5%) who did not have a splenectomy at their index hospitalization, leading to a

116 ft outcomes when compared most frequently to splenectomy-based protocols.

117 Moreover, splenectomy before RSD blocked monocyte trafficking to t

118 Splenectomy before subthreshold stress attenuated macrop

119 erm risk of sepsis in patients who underwent splenectomy before, during, and after implementation of

120 arious hematological disorders who underwent splenectomy between 1998 and 2009 were followed until de

121 uality Improvement Program data for elective splenectomy between January 1, 2005, and December 31, 20

122 a risk of splenic injury, which may require splenectomy, but predictors of such events remain uncert

123 spleens in oncologic patients who underwent splenectomy can be misinterpreted as a recurrence, espec

124 resent time, the use of immunotherapy before splenectomy can be recommended only in patients at high

125 Laparoscopic splenectomy can be safely performed during pregnancy.

126 n and antibody removal, without rituximab or splenectomy, can achieve long-term outcomes comparable t

127 Moreover, the hypothesis that incidental splenectomy carries a worse prognosis deserves attention

128 boembolic events, palpable splenomegaly, and splenectomy; chemotherapy exposure; leukemic transformat

129 The overall PR or CR to splenectomy combined with medical therapy was 84%.

130 he alloimmune response to the lymph nodes by splenectomy conferred the ability of B6.muMT(-/-) CD4 T

131 Splenectomy continues to provide the highest cure rate (

132 y), thymic irradiation (700 cGy), and native splenectomy (day 0), and received a 45-day course of int

133 Thirteen pigs underwent splenectomy (day 0); all received a blood transfusion.

134 th splenic injury, progression to incidental splenectomy decreased by 92% during the study period.

135 erioperative transfusion but did not undergo splenectomy demonstrated the worst prognosis on multivar

136 large datasets indicate contrasting rates of splenectomy depending on the expertise of the institutio

137 ing pneumococcal bacteremia after undergoing splenectomy despite having received numerous doses of PP

138 urrent guidelines recommend consideration of splenectomy, despite the known risks associated with sur

139 None of the patients with a history of splenectomy developed grade 3 or 4 hematotoxicity, and s

140 of Hbb-b2(Plt12/Plt12) mice was normal, and splenectomy did not correct the thrombocytopenia, sugges

141 hree patients required surgery: laparoscopic splenectomy due to infarct and abscess for 1 patient and

142 who were declared brain-dead or had emergent splenectomy due to trauma; control lungs (n = 20) were o

143 Splenectomy eliminated both the survival benefit of 6-hy

144 19% of whom underwent pre- or peritransplant splenectomy, experienced twice the adjusted risk of earl

145 nditioning regimen that included thymectomy, splenectomy, extracorporeal immunoadsorption of anti-alp

146 We studied 114 patients with ITP for whom splenectomy failed and who required additional therapy;

147 Median time to remission after splenectomy failure was 46 months (range, 1-437 months).

148 In regression analyses adjusting for age at splenectomy, follow-up time, sex, and calendar year of s

149 Furthermore, splenectomy following RSD prevented the recurrence of an

150 Patients underwent laparoscopic splenectomy for a range of hematological disorders betwe

151 help with patient selection before elective splenectomy for certain patients.

152 uraging evidence suggests that the effect of splenectomy for children is durable in the long term.

153 zed with rheumatoid vasculitis or to undergo splenectomy for Felty's syndrome, cervical spine fusion

154 nt the cases of three patients who underwent splenectomy for gastric carcinoid, gastric adenocarcinom

155 e pertaining to vascular complications after splenectomy for hematologic conditions and attempts to d

156 Elective splenectomy for hematologic conditions.

157 rdingly, the adverse effects and benefits of splenectomy for hematologic disorders and other conditio

158 ibed 15 or more consecutive patients who had splenectomy for ITP and that had data for 1 of these 3 o

159 Follow-up of patients who have undergone splenectomy for ITP reveals significant potential risks

160 We observed that splenectomy for ITP second-line treatment was more effec

161 Splenectomy for massive splenomegaly (>1500 g) provides

162 Splenectomy for massive splenomegaly can be performed sa

163 Splenectomy for massive splenomegaly was performed most

164 Current evidence supports alternatives to splenectomy for second-line management of patients with

165 scopic splenectomy as an alternative to open splenectomy for splenomegaly is regarded as controversia

166 utation in their granulocytes and undergoing splenectomy for therapeutical reasons.

167 onferred by C1 stimulation was eliminated by splenectomy, ganglionic-blocker administration or beta2-

168 oup for Nissen fundoplication, appendectomy, splenectomy, gastrostomy/jejunostomy, orchidopexy, and c

169 ary outcome-free survival rate was higher in splenectomy groups (84% for OS, 86% for LS) than Rituxim

170 Laparoscopic splenectomy has become the procedure of choice for most

171 Splenectomy has been a standard treatment for adult pati

172 efractory antibody-mediated rejection (AMR), splenectomy has been associated with surprisingly rapid

173 The role of splenectomy has been controversial in this patient popul

174 Age, splenectomy, hepatitis C, and smoking are significant un

175 A history of splenectomy, hepatitis C, smoking, or high white blood c

176 These beneficial effects of splenectomy hold true even for the most profoundly throm

177 Splenectomy, however, had no effect on monocyte accumula

178 ated with 2 or more therapy lines, including splenectomy, immunosuppressants, and rituximab.

179 h national inpatient register, who underwent splenectomy in 1970-2009.

180 spective cohort study of patients undergoing splenectomy in 2008 and 2009 using data from the America

181 1.9% (37.1% operable, 23.5% nonoperable) and splenectomy in 3.4% of patients (1.9% operable, 5.7% non

182 que group (0% vs. 10.5%; P=.03), requiring a splenectomy in 4 patients (4.7%).

183 ospitalization for rheumatoid vasculitis and splenectomy in Felty's syndrome decreased progressively

184 ospitalization for rheumatoid vasculitis and splenectomy in Felty's syndrome have decreased over the

185 The risk of hospitalization for splenectomy in Felty's syndrome was 71% lower in 1998-20

186 Splenectomy in mice with established HF reversed patholo

187 No study has directly compared rituximab to splenectomy in patients with chronic immune thrombocytop

188 was to compare the efficacy of Rituximab to splenectomy in persistent or chronic ITP patients.

189 y because of long-term immunosuppression and splenectomy in refractory cases.

190 usion and iron-chelation therapy, as well as splenectomy in specific cases.

191 ests an interaction of blood transfusion and splenectomy in their effect on survival paralleling the

192 Indications for splenectomy included: thrombocytopenia refractory to (64

193 Incidental accidental splenectomy increased the overall risk of mortality (HR:

194 nts, rituximab was found to be equivalent to splenectomy, indicating that this invasive surgical proc

195 time less than 60 min, absence of recipient splenectomy, interleukin-2 receptor antagonist induction

196 Splenectomy is a commonly performed operation; however,

197 A partial splenectomy is an alternative procedure, although its ut

198 Splenectomy is considered acceptable for patients with r

199 Laparoscopic splenectomy is feasible in patients with giant spleens.

200 Nonetheless, splenectomy is invasive, irreversible, associated with p

201 and persistent severe thrombocytopenia after splenectomy is minimal.

202 Splenectomy is not essential for successful ABO-incompat

203 s in only 4% of patients; therefore, routine splenectomy is not recommended.

204 The most widely recognized long-term risk of splenectomy is overwhelming bacterial infection.

205 sses diverse underlying conditions for which splenectomy is performed, diverse thrombotic complicatio

206 Splenectomy is usually proposed when a second-line thera

207 patible kidney transplantation have employed splenectomy, its utility is unproven.

208 se, lower incidence of treatment failure and splenectomy, less bleeding and fewer blood transfusions,

209 Splenectomy, loss of SIGN-R1(+) cells in the splenic mar

210 stinction between open (OS) and laparoscopic splenectomy (LS) was analyzed.

211 LDLT followed by thymoglobulin induction and splenectomy, maintenance with tacrolimus/cyclosporine (F

212 rs contributing to myelosuppression, whereas splenectomy may exert a protective effect.

213 al bacteremia in patients who have undergone splenectomy may indicate a genetically regulated failure

214 Splenectomy may play a role in the treatment of AMR refr

215 Splenectomy may remove an important antigen reservoir an

216 Splenectomy may reverse AMR by debulking PCs.

217 inage, and intra-abdominal bleeding (n = 3), splenectomy (n = 1), acute pancreatitis (n = 2), gastric

218 ng iron-chelating treatment and a history of splenectomy need regular ophthalmic checkups because the

219 and hospital characteristics, the choice of splenectomy (odds ratio, 0.93; 95% CI, 0.66-1.31) vs ang

220 per 1-year increase; 95% CI, 1.06-1.15) and splenectomy (odds ratio, 9.31; 95% CI, 2.57-33.7).

221 ertook this study to determine the impact of splenectomy on transfusion requirements in patients with

222 Age (two studies) and splenectomy (one study) had the strongest association wi

223 on without long-term B-cell suppression from splenectomy or anti-CD20.

224 previously reported, 3 Gy of TBI with either splenectomy or CD154 blockade induced mixed chimerism an

225 Splenectomy or depletion of splenic macrophages by lipos

226 Splenectomy or high-dose cortisone treatment had no effe

227 In peripheral blood from patients after splenectomy or in patients with sickle cell disease (SCD

228 plenomegaly and constitutional symptoms, and splenectomy or radiotherapy in selected patients.

229 Splenectomy or radiotherapy offers benefit, but careful

230 than OS, irrespective of the indication for splenectomy or the patient's clinical status.

231 ed the risk of splenic injury and incidental splenectomy (OR: 0.58; 95% CI: 0.41-0.80; and OR: 0.41;

232 he optimal timing for this therapy is before splenectomy, or after failure of splenectomy.

233 reference characteristics (no chemotherapy, splenectomy, or radiation therapy; male; attained age 28

234 ced- or conventional-intensity conditioning, splenectomy, or radiotherapy.

235 rates of in-hospital mortality, concomitant splenectomy, or total charges.

236 patients with TI and TM, age (P = 0.001) and splenectomy (P = 0.001) had the strongest association wi

237 ns of patients who received rituximab before splenectomy (P=0.0004).

238 In patients who underwent splenectomy, perioperative transfusion had no effect on

239 l antibody (Ab), four of whom also underwent splenectomy perioperatively.

240 omy alone (n=14), eculizumab alone (n=5), or splenectomy plus eculizumab (n=5), in addition to plasma

241 No patients treated with splenectomy plus eculizumab experienced graft loss.

242 t for patients manifesting early severe AMR, splenectomy plus eculizumab may provide an effective int

243 d eculizumab-alone groups at 1 year, whereas splenectomy plus eculizumab patients had almost no trans

244 In the hematologic malignancies, splenectomy produces a significant and longlasting resto

245 sk of surgery is an important consideration, splenectomy provides a high frequency of durable respons

246 usive trauma systems had significantly lower splenectomy rate (RR 0.79; 95% CI, 0.68-0.92) and lower

247 spitalization, leading to an overall delayed splenectomy rate of 1.2% (36 of 2967 patients).

248 m outcomes, such as readmissions and delayed splenectomy rate, are not well understood.

249 Secondary outcome was delayed splenectomy rate.

250 ivariate regression was performed to compare splenectomy rates, inpatient mortality, and costs betwee

251 Splenectomy reproduced antiinflammatory effects of enala

252 Splenectomy resulted in a dramatic enhancement of G-CSF-

253 Immunosuppression consisted of splenectomy, Rituximab (Anti-CD20), tacrolimus, sirolimu

254 ltirefractory ITP, defined as no response to splenectomy, rituximab, romiplostim, and eltrombopag.

255 e review 11 recipients, who underwent rescue splenectomy (RS) as a treatment of AMR within 3 months a

256 Splenectomy should be avoided.

257 Splenectomy should be considered safe and efficacious fo

258 ality and severe infections after incidental splenectomy should be kept in mind during surgery, and w

259 lihood of gastric variceal bleeding and that splenectomy should be performed to prevent hemorrhage.

260 In this study, we report that splenectomy significantly reduces systemic HMGB1 release

261 01, 25 consecutive adults with SLE underwent splenectomy specifically for thrombocytopenia.

262 platelet counts, concomitant ITP drugs, and splenectomy status) or by the number of previous ITP tre

263 re significant univariate risk factors, with splenectomy surfacing as the dominant risk factor over t

264 ression to assess the adjusted effect of the splenectomy technique on outcomes.

265 or those who received rituximab or underwent splenectomy, the overall graft survival was 94.5% (95% C

266 y, follow-up time, sex, and calendar year of splenectomy, there were no significant risk decreases af

267 options for symptomatic patients ranges from splenectomy to rituximab alone or combined with chemothe

268 The addition of splenectomy to this protocol only modestly added to the

269 mune thrombocytopenia, who had not undergone splenectomy, to receive the standard of care (77 patient

270 ty, rates of perioperative complications and splenectomy, total charges, and length of stay.

271 ared with 1% in patients who did not undergo splenectomy; venous thromboembolism (VTE) (deep venous t

272 ble living donor kidney transplantation with splenectomy versus a protocol involving intensive posttr

273 nous thrombosis and pulmonary embolus) after splenectomy was 4.3% compared with 1.7% in patients who

274 Early partial or complete response rate to splenectomy was 88%.

275 er of > or =8 was observed if the reason for splenectomy was a medical cause or if MCC vaccination oc

276 Splenectomy was associated with a higher adjusted risk o

277 nd 50% of children under the age of 6 years; splenectomy was associated with a significant improvemen

278 Indication for splenectomy was hereditary spherocytosis (111), immune t

279 y developed grade 3 or 4 hematotoxicity, and splenectomy was inversely associated with the incidence

280 No splenectomy was needed.

281 After May 2003, splenectomy was not performed and a protocol that involv

282 protection was abolished in animals in which splenectomy was performed 7 days before VNS and IRI.

283 er an average of 11 days of ST, laparoscopic splenectomy was performed for rescue.

284 Splenectomy was performed in 1344 patients (78.4%) for b

285 antation, 88 patients received chemotherapy; splenectomy was performed in 24 patients.

286 Splenectomy was performed in 36 of 799 readmitted patien

287 nts, and conventional evisceration including splenectomy was performed in remaining six recipients.

288 D) 3, HLA-DSA remained negative but a rescue splenectomy was performed.

289 ressure monitoring and blood sampling, and a splenectomy was performed.

290 Response to splenectomy was rated as: complete (CR: platelets >/=150

291 The presence of recipient splenectomy was significantly associated with the incide

292 as hampered by ineffective chemotherapy, and splenectomy was the major therapeutic approach to improv

293 Splenectomy was then performed.

294 ic artery ligation, hemiportocaval shunt, or splenectomy) was performed at the discretion of the oper

295 Predictors of splenic injury and incidental splenectomy were analyzed using multivariable logistic r

296 ered activity, and the protective effects of splenectomy were of particular interest.

297 with hematologic malignancies who underwent splenectomy were reviewed.

298 5 x 10(9)/L, more previous therapies, and/or splenectomy were somewhat lower.

299 Avoiding splenectomy while controlling hypersplenism by using cor

300 cient evidence to support the replacement of splenectomy with rituximab as a second-line treatment of

301 owever, risks depended on the indication for splenectomy, with SIRs varying from 3.4 (95% CI, 3.0-3.8